{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:52:44Z","timestamp":1775811164161,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To describe the survival and toxicity outcome from a single-centre experience in patients with squamous cell cancer of the anal canal (SCC-AC), related to the impact of technological advances in diagnostics and radiation techniques.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>A retrospective cohort study was performed after the approval of the institutional ethical committee (EK 478-21). We identified 142 patients in our registry, who received radical treatment for SCC-AC between 2000 and 2020. Fifty-five patients had FDG PET\/CT for initial staging and target volume delineation, 87.33% received concomitant chemoradiotherapy (CRT), 64 patients were treated with 3-dimensional conformal radiotherapy (3DRT) between 2000-2009, and 78 patients with intensity-modulated radiotherapy (IMRT) between 2009-2020. Endpoints for the analysis included locoregional relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS). Acute and late toxicities were also reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At a median follow-up of 31.2 months, the median overall survival was 135 months, 5-year LRFS was 73.1%, 5-year DFS was 65.3%, and 5-year CSS was 75.3%. The use of IMRT was associated with shorter treatment duration. In the univariate analysis, IMRT was associated with significantly improved DFS and CSS for the whole cohort and significantly improved DFS, OS, and CSS for patients who received CRT. In the multivariate analysis, IMRT was associated with the improvement of all survival paraments. The use of FDG PET\/CT did not translate into an improvement in the survival outcomes in both univariate and multivariate analyses. Grade-3 and more dermatological toxicities occurred less frequently, but hematological toxicities were more frequent in the IMRT-group. Late side effects and colostomies were less frequently reported in the IMRT group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The use of IMRT in the management of SCC-AC was associated with improvement of the oncological outcomes with improved toxicity profiles in this long-term single-centre experience.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.911925","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:32:09Z","timestamp":1654255929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Intensity-Modulated Radiotherapy Associated With Improved Survival Outcome in Anal Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Ahmed Allam","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsha","family":"Schlenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Heinzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Kintsler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Eble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","unstructured":"FerlayJ\n            LaversanneM\n            ErvikM\n            LamF\n            ColombetM\n            MeryL\n          Lyon, FranceInternational Agency for Research on CancerGlobal Cancer Observatory: Cancer Tomorrow2020"},{"key":"B2","article-title":"Variants of Squamous Cell Carcinoma of the Anal Canal and Perianal Skin and Their Relation to Human Papillomaviruses","author":"Frisch","year":"1999","journal-title":"Cancer Res"},{"key":"B3","article-title":"The Increasing Incidence of Anal Cancer: Can it be Explained by Trends in Risk Groups","volume":"71","author":"Van der Zee","year":"2013","journal-title":"Netherlands J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/BF02586980","article-title":"Combined Therapy for Cancer of the Anal Canal: A Preliminary Report","volume":"17","author":"Nigro","year":"2020","journal-title":"Dis Colon Rectum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil\/Mitomycin Versus Fluorouracil\/Cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or Cisplatin Chemoradiation With or Without Maintenance Chemotherapy for Treatment of Squamous-Cell Carcinoma of the Anus (ACT II): A Randomised, Phase 3, Open-Label, 2\u00d72 Factorial Trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A Phase II Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.10.016","article-title":"Patterns and Predictors of Relapse Following Radical Chemoradiation Therapy Delivered Using Intensity Modulated Radiation Therapy With a Simultaneous Integrated Boost in Anal Squamous Cell Carcinoma","volume":"106","author":"Shakir","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-Term Outcomes and Toxicities of a Large Cohort of Anal Cancer Patients Treated With Dose-Painted IMRT Per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctro.2021.02.002","article-title":"Intensity Modulated Radiotherapy for Anal Canal Squamous Cell Carcinoma: A 16-Year Single Institution Experience","volume":"28","author":"Jethwa","year":"2021","journal-title":"Clin Transl Radiat Oncol [Internet]"},{"key":"B11","first-page":"1080","article-title":"SySteMAtiC Review Pet Imaging in Anal Canal Cancer: A Systematic Review and Meta-Analysis","volume-title":"Br J Radiol","author":"Mahmud","year":"2017"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2016.05.009","article-title":"Metabolic Tumour Volume of Anal Carcinoma on 18FDG PET\/CT Before Combined Radiochemotherapy is the Only Independant Determinant of Recurrence Free Survival","volume":"85","author":"Mohammadkhani Shali","year":"2016","journal-title":"Eur J Radiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21037\/jgo.2018.03.03","article-title":"Utilization of Intensity Modulated Radiation Therapy for Anal Cancer in the United States","volume":"9","author":"Haque","year":"2018","journal-title":"J Gastrointest Oncol [Internet]"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-020-01539-x","article-title":"Management of Anal Cancer Patients-a Pattern of Care Analysis in German-Speaking Countries","volume":"15","author":"Martin","year":"2020","journal-title":"Radiat Oncol [Internet]"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.01.006","article-title":"The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma","volume":"98","author":"Pollom","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.02.012","article-title":"Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Anal Cancer","volume":"89","author":"Hodges","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.05.044","article-title":"Intensity Modulated Radiation Therapy Versus Conventional Radiation for Anal Cancer in the Veterans Affairs System","volume":"102","author":"Bryant","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31721","article-title":"Intensity-Modulated Radiotherapy Improves Survival and Reduces Treatment Time in Squamous Cell Carcinoma of the Anus: A National Cancer Data Base Study","volume":"124","author":"Elson","year":"2018","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2019.02.12","article-title":"Patterns of Care and Outcomes of Intensity Modulated Radiation Therapy Versus Three-Dimensional Conformal Radiation Therapy for Anal Cancer","volume":"10","author":"Lee","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"B20","unstructured":"ChuongMD\n            FreilichJM\n            HoffeSE\n            FulpW\n            WeberJM\n            AlmhannaK\n          Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal Department of Radiation Oncology2013"},{"key":"B21","doi-asserted-by":"crossref","unstructured":"KoerberSA\n            SlynkoA\n            HaefnerMF\n            KrugD\n            SchonewegC\n            KesselK\n          Efficacy and Toxicity of Chemoradiation in Patients With Anal Cancer-a Retrospective Analysis2014","DOI":"10.1186\/1748-717X-9-113"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112533","article-title":"Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance","volume":"13","author":"Possiel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up 5 on Behalf of the ESMO Guidelines Committee","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol [Internet]"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0060","article-title":"Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Cancer Netw [Internet]"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00053-021-00522-8","article-title":"S3-Leitlinie Analkarzinom","volume":"43","author":"Aigner","year":"2021","journal-title":"Coloproctol"},{"key":"B26","first-page":"19","article-title":"Prevalence of Human Papillomavirus Infection in Squamous Cell Carcinoma of the Anal Canal in a Northeast City in Brazil: Viral Genotyping and Clinical Aspects","volume-title":"Applied Cancer Research","author":"Janayna","year":"2017"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.06.159","article-title":"NRG Oncology\/RTOG 0529: Long-Term Outcomes of Dose-Painted Intensity Modulated Radiation Therapy, 5-Fluorouracil, and Mitomycin-C in Anal Canal Cancer","volume":"99","author":"Kachnic","year":"2017","journal-title":"Int J Radiat Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.911925\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:32:12Z","timestamp":1654255932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.911925\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":27,"alternative-id":["10.3389\/fonc.2022.911925"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.911925","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"911925"}}